Rocket Pharmaceuticals (RCKT) Stock Forecast, Price Target & Predictions

RCKT Stock Forecast

Rocket Pharmaceuticals stock forecast is as follows: an average price target of $42.00 (represents a 263.32% upside from RCKT’s last price of $11.56) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

RCKT Price Target

The average price target for Rocket Pharmaceuticals (RCKT) is $42.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $39.00. This represents a potential 263.32% upside from RCKT's last price of $11.56.

RCKT Analyst Ratings

Buy

According to 9 Wall Street analysts, Rocket Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RCKT stock is 0 'Strong Buy' (0.00%), 8 'Buy' (88.89%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Rocket Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 11, 2024	Whitney Ijem	Canaccord Genuity	$39.00	$17.09	128.20%	237.37%
Sep 18, 2024	Whitney Ijem	Canaccord Genuity	$38.00	$21.80	74.31%	228.72%
Sep 17, 2024	Michael E Ulz	Morgan Stanley	$45.00	$21.18	112.46%	289.27%
Apr 02, 2024	Richard Law	Goldman Sachs	$39.00	$26.72	45.96%	237.37%
Oct 03, 2022		Raymond James	$34.00	$15.96	113.03%	194.12%
Aug 09, 2022		Raymond James	$24.00	$15.17	58.21%	107.61%
Aug 12, 2021	Esther Rajavelu	UBS	$69.00	$30.80	124.03%	496.89%

The latest Rocket Pharmaceuticals stock forecast, released on Nov 11, 2024 by Whitney Ijem from Canaccord Genuity, set a price target of $39.00, which represents a 128.20% increase from the stock price at the time of the forecast ($17.09), and a 237.37% increase from RCKT last price ($11.56).

Rocket Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	4
Avg Price Target	-	$38.50	$40.25
Last Closing Price	$11.56	$11.56	$11.56
Upside/Downside	-100.00%	233.04%	248.18%

In the current month, the average price target of Rocket Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rocket Pharmaceuticals's last price of $11.56. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 18, 2024	Canaccord Genuity	Buy	Buy	Hold
Sep 17, 2024	Morgan Stanley	Overweight	Overweight	Hold
Apr 02, 2024	Goldman Sachs		Neutral	Initialise
Sep 13, 2023	Needham	Buy	Buy	Hold
Feb 01, 2023	Morgan Stanley		Overweight	Initialise
Dec 06, 2022	SVB Leerink	Outperform	Outperform	Hold
Oct 03, 2022	Chardan Capital	Buy	Buy	Hold
Oct 03, 2022	Raymond James	Outperform	Outperform	Hold
Sep 30, 2022	SVB Leerink	Outperform	Outperform	Hold
Sep 30, 2022	Evercore ISI	Outperform	Outperform	Hold
Sep 27, 2022	UBS	Buy	Buy	Hold
Aug 09, 2022	Raymond James	Outperform	Outperform	Hold
Jul 08, 2022	Raymond James		Outperform	Initialise
Jul 06, 2022	SVB Leerink	Outperform	Outperform	Hold
May 20, 2022	Chardan Capital	Buy	Buy	Hold
May 20, 2022	SVB Leerink	Outperform	Outperform	Hold
May 17, 2022	Needham	Buy	Buy	Hold
Feb 24, 2022	SVB Leerink	Outperform	Outperform	Hold

Rocket Pharmaceuticals's last stock rating was published by Canaccord Genuity on Sep 18, 2024. The company gave RCKT a "Buy" rating, the same as its previous rate.

Rocket Pharmaceuticals Financial Forecast

Rocket Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22
Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$182.22M	$147.04M	$120.94M	$85.91M	$21.26M	$24.92M	$3.82M	$2.08M	$31.30K	$564.31K	$1.84M	$111.11K
High Forecast	$182.22M	$147.04M	$120.94M	$85.91M	$21.26M	$24.92M	$3.82M	$2.08M	$31.30K	$564.31K	$1.84M	$111.11K
Low Forecast	$182.22M	$147.04M	$120.94M	$85.91M	$21.26M	$24.92M	$3.82M	$2.08M	$31.30K	$564.31K	$1.84M	$111.11K
# Analysts	2	2	2	2	1	1	1	4	9	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-

Rocket Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RCKT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Rocket Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22
# Analysts	2	2	2	2	1	1	1	4	9	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-63.95M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict RCKT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Rocket Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Rocket Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22
# Analysts	2	2	2	2	1	1	1	4	9	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-64.36M
Avg Forecast	$12.68M	$-5.20M	$-16.51M	$-34.73M	$-58.29M	$-52.05M	$-66.88M	$-67.14M	$-68.67M	$-70.65M	$-67.98M	$-75.14M
High Forecast	$12.68M	$-5.20M	$-16.51M	$-34.73M	$-58.29M	$-52.05M	$-66.88M	$-64.09M	$-58.32M	$-70.65M	$-67.98M	$-75.14M
Low Forecast	$12.68M	$-5.20M	$-16.51M	$-34.73M	$-58.29M	$-52.05M	$-66.88M	$-72.22M	$-74.32M	$-70.65M	$-67.98M	$-75.14M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.86%

Rocket Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RCKT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Rocket Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22
# Analysts	2	2	2	2	1	1	1	4	9	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	$19.05M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-

Rocket Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RCKT last annual SG&A of $19.05M (Dec 22).

Rocket Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22
# Analysts	2	2	2	2	1	1	1	4	9	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.94
Avg Forecast	$0.13	$-0.06	$-0.18	$-0.37	$-0.62	$-0.55	$-0.71	$-0.71	$-0.73	$-0.75	$-0.72	$-0.80
High Forecast	$0.13	$-0.06	$-0.18	$-0.37	$-0.62	$-0.55	$-0.71	$-0.68	$-0.62	$-0.75	$-0.72	$-0.80
Low Forecast	$0.13	$-0.06	$-0.18	$-0.37	$-0.62	$-0.55	$-0.71	$-0.77	$-0.79	$-0.75	$-0.72	$-0.80
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.18%

According to undefined Wall Street analysts, Rocket Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RCKT previous annual EPS of $NaN (undefined).

Rocket Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
STRO	Sutro Biopharma	$2.09	$13.00	522.01%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
LRMR	Larimar Therapeutics	$4.32	$17.00	293.52%	Buy
RCKT	Rocket Pharmaceuticals	$11.92	$42.00	252.35%	Buy
RGNX	REGENXBIO	$8.47	$29.75	251.24%	Buy
QURE	uniQure	$16.46	$53.67	226.06%	Buy
SLDB	Solid Biosciences	$4.46	$12.00	169.06%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
CYTK	Cytokinetics	$47.78	$90.00	88.36%	Buy
DYN	Dyne Therapeutics	$26.16	$49.00	87.31%	Buy
MRUS	Merus	$44.90	$81.25	80.96%	Buy
PCVX	Vaxcyte	$89.86	$148.80	65.59%	Buy
REPL	Replimune Group	$11.72	$19.00	62.12%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
MGTX	MeiraGTx	$6.40	$9.00	40.63%	Buy
MIRM	Mirum Pharmaceuticals	$42.65	$57.00	33.65%	Buy
RYTM	Rhythm Pharmaceuticals	$56.80	$64.50	13.56%	Buy
VRDN	Viridian Therapeutics	$20.82	$22.75	9.27%	Buy

RCKT Forecast FAQ

Is Rocket Pharmaceuticals a good buy?

Yes, according to 9 Wall Street analysts, Rocket Pharmaceuticals (RCKT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 88.89% of RCKT's total ratings.

What is RCKT's price target?

Rocket Pharmaceuticals (RCKT) average price target is $42 with a range of $39 to $45, implying a 263.32% from its last price of $11.56. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Rocket Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for RCKT stock, the company can go up by 263.32% (from the last price of $11.56 to the average price target of $42), up by 289.27% based on the highest stock price target, and up by 237.37% based on the lowest stock price target.

Can Rocket Pharmaceuticals stock reach $20?

RCKT's average twelve months analyst stock price target of $42 supports the claim that Rocket Pharmaceuticals can reach $20 in the near future.

What are Rocket Pharmaceuticals's analysts' financial forecasts?

Rocket Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $52.08M (high $52.08M, low $52.08M), average EBITDA is $0 (high $0, low $0), average net income is $-244M (high $-241M, low $-249M), average SG&A $0 (high $0, low $0), and average EPS is $-2.595 (high $-2.563, low $-2.649). RCKT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $536.12M (high $536.12M, low $536.12M), average EBITDA is $0 (high $0, low $0), average net income is $-43.746M (high $-43.746M, low $-43.746M), average SG&A $0 (high $0, low $0), and average EPS is $-0.465 (high $-0.465, low $-0.465).